SEARCH

SEARCH BY CITATION

References

  • 1
    McCormick D, Kibbe PJ, Morgan SW. Colon cancer: prevention, diagnosis, treatment. Gastroenterol Nurs 2002; 25: 20411; quiz, 11-2.
  • 2
    Krishnamoorthy S, Honn KV. Eicosanoids in tumor progression and metastasis. Subcell Biochem 2008; 49: 14568.
  • 3
    Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 2003; 253: 1419.
  • 4
    Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 2000; 17: 10957.
  • 5
    Furstenberger G, Krieg P, Muller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis? Int J Cancer 2006; 119: 224754.
  • 6
    Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001; 61: 630712.
  • 7
    Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 22940.
  • 8
    Zuo X, Wu Y, Morris JS et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 2006; 25: 122541.
  • 9
    Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001; 22: 176573.
  • 10
    Kelavkar U, Cohen C, Eling T, Badr K. 15-lipoxygenase-1 overexpression in prostate adenocarcinoma. Adv Exp Med Biol 2002; 507: 13345.
  • 11
    Kelavkar UP, Harya NS, Hutzley J et al. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins Other Lipid Mediat 2007; 82: 18597.
  • 12
    Hsi LC, Wilson LC, Eling TE. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 2002; 277: 4054956.
  • 13
    Hsi LC, Wilson L, Nixon J, Eling TE. 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J Biol Chem 2001; 276: 3454552.
  • 14
    Yoshinaga M, Buchanan FG, DuBois RN. 15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins Other Lipid Mediat 2004; 73: 11122.
  • 15
    Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999; 59: 3606.
  • 16
    Shureiqi I, Wojno KJ, Poore JA et al. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 1999; 20: 198595.
  • 17
    Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H. Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 2007; 51: 5207.
  • 18
    Liu C, Xu D, Sjoberg J, Forsell P, Bjorkholm M, Claesson HE. Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res 2004; 297: 617.
  • 19
    Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene 2009; 28: 1496505.
  • 20
    Shureiqi I, Zuo X, Broaddus R et al. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J 2007; 21: 74353.
  • 21
    Nixon JB, Kim KS, Lamb PW, Bottone FG, Eling TE. 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 715.
  • 22
    Kim JS, Baek SJ, Bottone FG Jr, Sali T, Eling TE. Overexpression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol Cancer Res 2005; 3: 5117.
  • 23
    Shureiqi I, Wu Y, Chen D et al. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 2005; 65: 1148692.
  • 24
    Wu Y, Fang B, Yang XQ et al. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 2008; 16: 88692.
  • 25
    Zhu H, Glasgow W, George MD et al. 15-lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity. Int J Cancer 2008; 123: 27419.
  • 26
    Shureiqi I, Chen D, Lotan R et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000; 60: 684650.
  • 27
    Kamitani H, Taniura S, Ikawa H, Watanabe T, Kelavkar UP, Eling TE. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis 2001; 22: 18791.
  • 28
    Hennig R, Kehl T, Noor S et al. 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 2007; 9: 91726.
  • 29
    Sendobry SM, Cornicelli JA, Welch K et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol 1997; 120: 1199206.
  • 30
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 31
    Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008; 7: 103646.
  • 32
    Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 2004; 64: 877881.
  • 33
    Philips BJ, Dhir R, Hutzley J, Sen M, Kelavkar UP. Polyunsaturated fatty acid metabolizing 15-Lipoxygenase-1 (15-LO-1) expression in normal and tumorigenic human bladder tissues. Appl Immunohistochem Mol Morphol 2008; 16: 15964.
  • 34
    Shureiqi I, Jiang W, Zuo X et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 2003; 100: 996873.
  • 35
    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 23952.
  • 36
    Toda D, Ota T, Tsukuda K et al. Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells. Anticancer Res 2006; 26: 12934.
  • 37
    Nobumoto A, Nagahara K, Oomizu S et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008; 18: 73544.
  • 38
    Li M, Xie J, Cheng L et al. Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene. Cancer Invest 2008; 26: 90512.
  • 39
    Mazumdar A, Wang RA, Mishra SK et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001; 3: 307.
  • 40
    Molli PR, Singh RR, Lee SW, Kumar R. MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene. Oncogene 2008; 27: 197180.
  • 41
    Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K, Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis 2003; 20: 1924.
  • 42
    Giannini R, Cavallini A. Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res 2005; 25: 428792.
  • 43
    Mahoney MG, Simpson A, Jost M et al. Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene 2002; 21: 216170.